SHR-4602 clinical trials
Also written SHR-4602.
How each study uses SHR-4602 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SHR-4602 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SHR-4602
- 4
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Shanghai Hengrui Pharmaceutical Co., Ltd. (1) · Fudan University (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Atridia Pty Ltd. (1)
Often tested with
Tested in the same studies.
Dalpiciclib (1) · Pyrotinib (1) · Trastuzumab rezetecan (1) · Adebrelimab (1) · Camrelizumab (1) · Tizetatug rezetecan (1) · Pertuzumab (1) · Trastuzumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test SHR-4602.
- Apr 2027A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid TumorsPhase 2 · Shanghai Hengrui Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses SHR-4602 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as SHR-4602
- A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid TumorsNot yet recruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06704828Written as SHR-4602
- A Study of SHR-4602 in Subjects With Advanced Malignant Solid TumorsRecruitingPhase 1Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05819684Written as SHR-4602 for injection
- SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid TumorsTerminatedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT06516926Written as SHR-4602
- A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid TumorsWithdrawnPhase 1Atridia Pty Ltd.NCT06560138Written as SHR-4602